Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.35 |
| ▸ | SCD | O00767 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 8/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22030882 | 0.88 | NNMT (0.46) | NNMTGABRA1SCD5SCDRET | |
| SCHEMBL20160375 | 0.84 | NNMT (0.43) | NNMTGABRA1SCD5SCDRET | |
| SCHEMBL23126240 | 0.84 | NNMT (0.43) | NNMTGABRA1SCD5SCD | |
| SCHEMBL20069574 | 0.84 | NNMT (0.43) | NNMTGABRA1SCD5SCDRET | |
| SCHEMBL21159149 | 0.75 | RET (0.47) | RETTRPC6HCRTR2 | |
| SCHEMBL20153138 | 0.70 | PDE10A (0.45) | RETHCRTR2 | |
| SCHEMBL20070578 | 0.69 | MGLL (0.45) | RET | |
| SCHEMBL22811914 | 0.68 | RET (0.46) | RET | |
| SCHEMBL20154557 | 0.68 | RET (0.46) | RET | |
| SCHEMBL23126207 | 0.68 | RET (0.51) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | NNMT 2639/4885GABRA1 2005/4885SCD5 4849/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | NNMT 2639/4885GABRA1 2005/4885SCD5 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.